Neothetics to Present at the 16th Annual Needham Healthcare Conference
29 Marzo 2017 - 2:00PM
Neothetics, Inc. (NASDAQ:NEOT) today announced that Susan A.
Knudson, Neothetics’ Chief Financial Officer, will present at the
16th Annual Needham Healthcare Conference on Wednesday, April 5th
at 12:50 PM, Eastern Time at the Westin Grand Central Hotel
in New York City.
To receive Neothetics' press releases and other investor
information, please go to the Investor Relations page of the
company's website at investors.neothetics.com and register for
email alerts.
About LIPO-202
LIPO-202 is a proprietary, first-in-class injectable formulation
of the well-known long-acting ß2-adrenergic receptor agonist,
salmeterol xinafoate, which is an active ingredient of FDA-approved
inhaled products such as SEREVENT DISKUS®, ADVAIR HFA® and ADVAIR
DISKUS®. Our studies suggest that salmeterol xinafoate activates ß2
-adrenergic receptors on fat cells, triggering the body’s natural
process of metabolizing stored triglycerides (fat) resulting in a
reduction in size and volume of the fat cells in the treatment area
without damage of nearby tissues. LIPO-202 has an extremely
favorable safety profile, with little to no adverse post treatment
effects. LIPO-202 is being evaluated for the reduction of
submental fat commonly referred to as a double-chin.
About Neothetics, Inc.
Neothetics is a San Diego based clinical-stage specialty
pharmaceutical company developing therapeutics for the aesthetic
market. Our initial focus is on localized fat reduction and body
contouring. Our lead product candidate, LIPO-202, is a
first-in-class injectable formulation of the long-acting
ß2-adrenergic receptor agonist, salmeterol xinafoate, which is an
active ingredient in the U.S. Food and Drug Administration, or FDA,
approved inhaled products SEREVENT DISKUS®, ADVAIR HFA® and ADVAIR
DISKUS®. For more information on Neothetics, please visit
www.neothetics.com. Neothetics, LIPO-202, LIPO-102 and the
Neothetics logo are trademarks or registered trademarks of
Neothetics, Inc. Other names and brands may be claimed as the
property of others.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include, but are not limited to,
statements regarding the ability to develop a modified
formulation of LIPO-202, timing of conducting and obtaining results
from Phase 2 trials and proof of concept study with a modified
formulation of LIPO-202, whether our modified formulation of
LIPO-202 is able to demonstrate positive results,
Neothetics’ plans to research, develop and commercialize
LIPO-202 and other product candidates, our expectations regarding
the potential market size and opportunity of LIPO-202, as well as
expected timing for reporting results from clinical trials. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. These forward-looking statements
are based upon Neothetics’ current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks and uncertainties associated
with clinical trials, such as the ability to timely initiate
clinical trials and enroll a sufficient number of patients on a
timely basis into clinical trials, the extent to which top-line
data is available and whether the clinical trials achieve positive
results, product development activities, obtaining regulatory
approval to commercialize LIPO-202 and other product candidates,
Neothetics’ use of cash, and the need to raise additional funding,
when needed, in order to conduct our clinical trials and other
business, the degree of market acceptance of LIPO-202 by
physicians, patients and others in the medical community, our
reliance on third parties, including third-party suppliers for
manufacturing and distribution of products, regulatory developments
in the United States and foreign countries, Neothetics’ ability to
obtain and maintain intellectual property protection for LIPO-202
and its product candidates, competition in the aesthetics industry
and other market conditions. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Neothetics undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.
Investors should consult all of the information set forth herein
and should also refer to the risk factor disclosure set forth in
the reports and other documents the company files with
the SEC available at www.sec.gov, including without
limitation, Neothetics’ Form 10-K for the year ended December 31,
2016 and subsequent Quarterly Reports on Form 10-Q.
COMPANY CONTACTS:
Susan A. Knudson
Chief Financial Officer
858-500-7780
sknudson@neothetics.com
Fara Berkowitz, R.Ph, Pharm.D
Senior Director, Investor Relations and Corporate Development
646-494-1589
fberkowitz@neothetics.com
Grafico Azioni NEOTHETICS, INC. (NASDAQ:NEOT)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni NEOTHETICS, INC. (NASDAQ:NEOT)
Storico
Da Gen 2024 a Gen 2025